Walgreens Boots Alliance stock tracks debt reduction and margin pressure

Walgreens Boots Alliance (US9314271019) stock is shaped by a $13.7 billion transaction backdrop, a fiscal 2025 operating loss of $232 million, and third-quarter fiscal 2025 net sales of $39.0 billion. The company also reported adjusted EPS of $0.38 for the quarter ended 31 May 2025, a year-over-year decline from $0.63, according to its investor relations materials.

$39.0 billion sales

For investors, the key number is revenue scale versus profitability. Walgreens Boots Alliance said third-quarter fiscal 2025 net sales reached $39.0 billion, while operating loss widened to $0.232 billion in fiscal 2025, showing that top-line size did not yet translate into earnings stability.

The same reporting period included adjusted EPS of $0.38 in the quarter ended 31 May 2025, down from $0.63 a year earlier. That 39.7% drop underscores how quickly earnings power can shift when pharmacy reimbursement, retail traffic, and restructuring costs move in the wrong direction.

Debt and loss pressure

The company’s fiscal 2025 operating loss of $232 million provides the clearest snapshot of the pressure on the business model. A loss at that level matters more than headline sales because it shows how little cushion remains after fixed costs and pharmacy margin compression.

The $13.7 billion deal backdrop adds another layer. Walgreens Boots Alliance agreed to a transaction that may change how investors think about leverage, portfolio mix, and the balance sheet, especially after a year when earnings and operating profit moved in the wrong direction.

Margin matters most

Walgreens Boots Alliance stock is still a numbers story, not a narrative story. The latest figures show $39.0 billion in quarterly net sales, $232 million in fiscal 2025 operating loss, and adjusted EPS of $0.38 versus $0.63 a year earlier, which together point to a business under heavy margin strain.

That combination is more useful than any broad sector label. Revenue remains large, but the gap between sales and profit is wide enough that even a modest improvement in reimbursement, store efficiency, or cost control could matter more than the size of the headline sales base.

Retail pharmacy core

The most representative business line remains retail pharmacy and prescription dispensing, where Walgreens Boots Alliance generates the bulk of its customer traffic and recurring revenue. That core matters because the latest quarter showed how sensitive the company is to pharmacy economics and operating expense discipline.

For a company with third-quarter fiscal 2025 net sales of $39.0 billion, the pharmacy channel is the main lever that can either stabilize earnings or keep pressure on margins. The current figures show why investors keep focusing on execution rather than scale alone.

Closing level

Shares in Walgreens Boots Alliance last traded at $11.84 on Nasdaq as of 29 July 2026. The stock remains tied to whether sales scale can eventually support better earnings conversion after fiscal 2025 operating loss and quarter-end EPS pressure.